Tango Therapeutics (TNGX) Amortization of Deferred Charges (2020 - 2026)

Tango Therapeutics' Amortization of Deferred Charges history runs 7 years deep, the most recent figure standing at $972000.0 for Q1 2026.

• On a quarterly basis, Amortization of Deferred Charges fell 3.95% year-over-year to $972000.0 in Q1 2026; TTM through Mar 2026 was $3.9 million, a 2.32% increase from a year earlier, with the FY2025 full-year figure at $4.0 million, up 5.77% from the prior year.
• Amortization of Deferred Charges advanced to $972000.0 in Q1 2026 per TNGX's latest filing, from $958000.0 in the prior quarter.
• Across five years, Amortization of Deferred Charges topped out at $1.0 million in Q2 2025 and bottomed at $361000.0 in Q1 2022.
• The 5-year median for Amortization of Deferred Charges is $925000.0 (2024), against an average of $864941.2.
• Across the five-year window, Amortization of Deferred Charges soared 213.67% in 2022 and decreased 3.95% in 2026, its largest moves.
• Year by year, Amortization of Deferred Charges stood at $882000.0 in 2022, then grew by 3.63% to $914000.0 in 2023, then climbed by 4.38% to $954000.0 in 2024, then grew by 0.42% to $958000.0 in 2025, then increased by 1.46% to $972000.0 in 2026.
• Per Business Quant, the three latest TNGX Amortization of Deferred Charges figures stand at $972000.0 (Q1 2026), $958000.0 (Q4 2025), and $973000.0 (Q3 2025).